IRLAB’s CEO intends to step down during the first quarter of 2027

Gothenburg, September 3, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, announces today that Kristina Torfgård has informed the Board of Directors that she wishes to step down from her position as CEO. She will remain in the CEO role until the first quarter of 2027, creating good conditions for a smooth transition to her successor. The Board of Directors will immediately initiate the work to ensure a well-structured leadership transition.

New number of shares and votes in IRLAB Therapeutics AB

IRLAB publishes interim report for the period January – June 2026